Summary of Cullinan Therapeutics Conference Call Company Overview - **Company**: Cullinan Therapeutics (NasdaqGS: CGEM) - **Year**: 2026 is highlighted as a potentially defining year for the company with multiple milestones across programs, particularly focusing on T-cell engager programs CLN-978 and CLN-049 [17][21] Key Programs and Developments CLN-978 (CD19xCD3 T-cell engager) - **Indications**: Targeting autoimmune diseases such as lupus, rheumatoid arthritis (RA), and Sjögren's disease - **Differentiation**: Claimed to be a potential best-in-class molecule with high affinity binding for CD19 and small molecular size for better tissue penetration [17][18] - **Clinical Data Timeline**: - Q2 2026: Initial clinical data from systemic lupus erythematosus (SLE) and RA - Q3 2026: Initial multi-dose data from RA - Q4 2026: Initial data from Sjögren's disease study [18] - **Market Interest**: The B-cell depletion space remains attractive, as evidenced by recent acquisitions in the sector [18] CLN-049 (FLT3xCD3 T-cell engager) - **Indication**: Focused on acute myeloid leukemia (AML) - **Efficacy Data**: Presented compelling monotherapy efficacy data at ASH, with Fast Track designation from the FDA received [19] - **Clinical Development**: - Plans to initiate a phase 1/2 study in combination with venetoclax in the frontline setting by the end of 2026 [19][94] - Aiming for a pivotal study in relapsed refractory disease [19] Zipalertinib - **Milestone**: Completed NDA submission, marking a significant achievement for the company [20] Financial Position - **Cash Reserves**: Over $430 million reported at the end of the previous year, providing a runway into 2029 to advance programs [21] Competitive Landscape - **Positioning**: CLN-978 is positioned against other CD19 T-cell engagers, with a focus on its high binding affinity and small size for better tissue penetration [42][43] - **Competitors**: Companies like Roche, Novartis, Merck, and GSK are mentioned as competitors, with some being further behind in development [42][43] Clinical Insights and Data - **B-cell Depletion**: Emphasized the importance of deep B-cell depletion for achieving treatment-free remission in autoimmune diseases [26][27] - **Durability of Response**: Noted that some patients have achieved treatment-free responses lasting several years, particularly in diseases like systemic lupus erythematosus [33] - **Safety Profile**: Initial studies showed favorable safety profiles with low rates of cytokine release syndrome (CRS) [67][92] Future Outlook - **Upcoming Data**: Anticipated updates at ASH or EHA, with a focus on further dose escalation and durability of response [95][96] - **Regulatory Pathway**: Clear development pathway for AML with potential for approval in relapsed refractory disease through a single-arm study [94] Conclusion - **Strategic Focus**: Cullinan Therapeutics is poised for a significant year in 2026 with multiple clinical milestones, a strong financial position, and a competitive edge in the T-cell engager space, particularly in autoimmune diseases and AML [21][94]

Core Insights - Cullinan Therapeutics is advancing multiple clinical programs with significant milestones expected throughout 2026, including initial data for CLN-978 in autoimmune diseases and updates on zipalertinib for oncology [1][2][3] Financial Overview - As of December 31, 2025, the company reported cash and investments totaling $439.0 million, providing a financial runway into 2029 [1][10] - Research and development expenses for Q4 2025 were $42.9 million, an increase from $40.5 million in Q4 2024, while total R&D expenses for the full year 2025 reached $187.4 million compared to $142.9 million in 2024 [5][11] - General and administrative expenses for Q4 2025 were $12.3 million, down from $14.6 million in Q4 2024, with full-year G&A expenses slightly increasing to $54.2 million from $54.0 million [5][11] - The net loss attributable to Cullinan was $50.7 million for Q4 2025, compared to $47.6 million in Q4 2024, and $219.9 million for the full year 2025, up from $167.4 million in 2024 [5][11] Clinical Development Highlights - CLN-978, a CD19xCD3 bispecific T cell engager, is set to provide initial data for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in Q2 2026, with repeat dosing data expected in Q3 2026 [4] - Zipalertinib's rolling NDA submission has been completed, and the REZILIENT3 frontline study has been fully enrolled, with top-line results anticipated by the end of 2026 [1][3] - CLN-049, targeting acute myeloid leukemia (AML), is expected to advance to registrational development following promising clinical data and is set to initiate monotherapy dose expansion cohorts in Q2 2026 [4][8] Strategic Partnerships and Collaborations - The company is collaborating with Taiho Oncology on zipalertinib, which is nearing regulatory approval for treating EGFR ex20ins non-small cell lung cancer (NSCLC) [3][8] - Genrix Bio is enrolling a Phase 1 study for velinotamig in autoimmune diseases, with initial clinical data expected in Q4 2026, which Cullinan plans to leverage for global development [4]

Summary of Cullinan Therapeutics Conference Call Company Overview - **Company**: Cullinan Therapeutics (NasdaqGS: CGEM) - **Date**: February 19, 2026 - **Event**: Citi's Virtual Oncology Leadership Summit Key Points Oncology Pipeline Development - **2026 Significance**: Cullinan Therapeutics anticipates multiple catalysts across its oncology pipeline, particularly for T-cell engagers CLN-978 and CLN-049 [6][72] - **CLN-978**: A CD19 by CD3 T-cell engager targeting autoimmune diseases with a global development program aimed at lupus, rheumatoid arthritis (RA), and Sjögren's disease. The molecule is noted for its high binding affinity and potential to replace monoclonal antibodies [7][8] - **CLN-049**: A FLT3 x CD3 T-cell engager for acute myeloid leukemia (AML), presenting a first-in-class opportunity. The company aims to transition from dose escalation to dose expansion and is utilizing Fast Track designation from the FDA to select a recommended phase II dose [9][11] Clinical Data and Efficacy - **CLN-049 Efficacy**: Presented compelling monotherapy efficacy data at ASH 2025, with a complete response rate of approximately 30% and durable responses observed in patients, including those with P53 mutations [20][41] - **Safety Profile**: The safety profile of CLN-049 is favorable, with a lower incidence of cytokine release syndrome (CRS) compared to other T-cell engagers [21][22] Market Opportunity - **AML Market Size**: Approximately 20,000 new AML cases annually in the US, with a significant relapse/refractory patient pool. The potential market for CLN-049 in this segment is estimated to be a billion-dollar opportunity, with further expansion into frontline settings potentially unlocking multi-billion dollar opportunities [57][58] Financial Position - **Cash Reserves**: As of December 2025, Cullinan reported over $430 million in cash, providing a runway into 2029 to support ongoing programs [15] Zipalertinib Development - **Partnership with Taiho**: Zipalertinib, an EGFR exon 20 tyrosine kinase inhibitor, is in collaboration with Taiho, which is completing a rolling NDA submission. The agreement includes a 50/50 profit share in the US and $130 million in regulatory milestones [12][61] - **Market Potential**: The annual diagnosis of exon 20 non-small cell lung cancer in the US is estimated at 3,000-5,000 patients, presenting a significant market opportunity [60] Future Milestones - **Upcoming Data Releases**: Data updates for CLN-049 are expected in the second half of 2026, with dose expansion cohorts planned for initiation in Q2 2026 [70][71] - **Regulatory Pathway**: The company is confident in pursuing accelerated approval pathways for both CLN-049 and zipalertinib, with clear development strategies outlined [46][48] Conclusion - **2026 Outlook**: Cullinan Therapeutics is positioned for a transformative year with multiple catalysts across its oncology and autoimmune pipelines, aiming to create shareholder value through strategic advancements and regulatory approvals [72]

Summary of Cullinan Therapeutics 2026 Conference Call Company Overview - **Company**: Cullinan Therapeutics (NasdaqGS: CGEM) - **Focus**: Development of T cell engager programs for autoimmune diseases and oncology Key Priorities and Portfolio - **2026 Significance**: First year with catalysts across the entire portfolio, particularly for two high-priority T cell engager programs: - **CLN-978**: CD19 x CD3 bispecific T cell engager for autoimmune diseases - **CLN-049**: FLT3 x CD3 T cell engager for acute myeloid leukemia (AML) [5][6] CLN-978 Program - **Potential**: Considered a best-in-class molecule for autoimmune diseases with a global development program targeting lupus, rheumatoid arthritis (RA), and Sjögren's disease [6] - **Differentiation**: High binding affinity for CD19, small molecular size for better tissue penetration, and subcutaneous administration convenience [6] - **Data Readouts**: Planned throughout 2026 for all three indications [6] - **Market Interest**: B cell depletion remains a hot area, with strategic acquisitions in the sector, indicating strong market interest [7] CLN-049 Program - **Potential**: First-in-class potential for a broad group of AML patients, with compelling monotherapy efficacy data presented at ASH [8] - **Regulatory Designation**: Received Fast Track designation from the FDA, facilitating a pivotal single-arm study for potential approval [8] - **Commercial Opportunity**: Aiming for significant commercial potential in the AML market, with plans for a combination study later in the year [8][34] Financial Position - **Cash Reserves**: Over $430 million reported at the end of 2025, providing a runway into 2029 to advance programs without immediate capital raising needs [9] Clinical Development Updates - **Enrollment Progress**: Completed first two dose cohorts for CLN-978 and currently accruing into the 30 microgram dose level for lupus and RA studies [11] - **Efficacy Expectations**: Anticipating a dose-response effect for B cell depletion in upcoming data releases [14][15] Competitive Landscape - **Market Position**: The company aims to be the first to present company-sponsored data for a CD19 T-cell engager, enhancing competitive positioning [19] - **Strategic Acquisitions**: Acquired a BCMA TCE to expand the reach in autoimmune diseases, allowing for a broader patient base [27][28] Future Plans - **Pivotal Studies**: Plans to initiate a phase 2 single-arm study for CLN-049 in 2027, targeting relapsed refractory AML patients [40] - **Combination Studies**: Intent to begin a phase 1b/2 combination study with AZA in previously untreated AML patients [37] Zipalertinib Program - **NDA Submission**: Completion of the relapsed study marks a significant milestone, with Taiho leading further development [41] - **Financial Impact**: Potential for $130 million in regulatory milestones and a 50/50 profit share in the U.S. [42] Conclusion - **Outlook for 2026**: A defining year for Cullinan Therapeutics with multiple catalysts and significant potential in both autoimmune diseases and oncology, supported by a strong financial position and strategic development plans [9][43]

Core Insights - Cullinan Therapeutics is focusing on high-conviction clinical stage programs, particularly CLN-049 and CLN-978, with promising data expected to be presented at upcoming conferences [2][3] - The company has discontinued the CLN-619 and CLN-617 programs based on emerging clinical data, streamlining its pipeline towards T cell engagers [3] - As of September 30, 2025, Cullinan reported cash and investments totaling $475.5 million, providing a financial runway into 2029 [1][12] Clinical Programs - CLN-049, a FLT3xCD3 bispecific T cell engager, demonstrated a ~30% complete response rate in heavily pretreated patients with relapsed/refractory acute myeloid leukemia (AML) [1][12] - Initial data for CLN-978, targeting systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), is expected to be shared in the first half of 2026 [1][6] - The Phase 1 OUTRACE Program for CLN-978 is currently enrolling patients across multiple studies [6] Financial Performance - Research and development expenses for Q3 2025 were $42.0 million, up from $35.5 million in Q3 2024 [12][15] - General and administrative expenses were $13.6 million for Q3 2025, slightly higher than $13.3 million in Q3 2024 [12][15] - The net loss attributable to Cullinan for Q3 2025 was $50.6 million, compared to $40.6 million for the same period in 2024 [12][16] Strategic Focus - The company is strategically concentrating resources on T cell engagers, which are seen as having transformative potential in immunology and oncology [3][2] - A positive pre-NDA meeting with the FDA has set the stage for a rolling submission of an NDA for zipalertinib in relapsed EGFR ex20ins non-small cell lung cancer (NSCLC) by year-end 2025 [3][7]

Core Insights - Taiho Oncology Inc. and Cullinan Therapeutics Inc. presented new data from the CNS involvement cohort of the REZILIENT2 study for zipalertinib in advanced or metastatic NSCLC with specific EGFR mutations, to be showcased at ESMO Congress 2025 [1] Summary of Preliminary Efficacy - The ongoing Phase 2b REZILIENT2 trial includes a CNS involvement cohort where 32 patients received zipalertinib 100 mg orally twice daily, with a median of 2 prior lines of therapy [3] - Among the enrolled patients, 21 had ex20ins mutations and 13 had other uncommon mutations [3] - In the evaluable population (n=16), the intracranial objective response rate was 31.3%, with one complete response, and the intracranial disease control rate was 68.8% [4] - The median intracranial duration of response was 8.1 months [4] - The preliminary systemic objective response rate was 27.6% with a median duration of response of 7.6 months [5] - Intracranial antitumor activity was comparable to overall systemic anticancer activity [5] Summary of Preliminary Safety and Tolerability - Zipalertinib was well tolerated at the administered dose, with no new safety signals reported [6] - Treatment-related adverse events of grade 3 or higher occurred in 25% of patients, including anemia and interstitial lung disease, with one death attributed to interstitial lung disease [6] - Following the data release, CGEM stock increased by 4.96% to $7.77 [6]

Core Insights - Black Diamond Therapeutics, Inc. (BDTX) and Cullinan Therapeutics, Inc. (CGEM) are both clinical-stage biotech companies focused on developing therapies for cancer, particularly targeting specific oncogenic mutations [2][3] BDTX Overview - BDTX is advancing its lead candidate, silevertinib, a fourth-generation EGFR MasterKey inhibitor aimed at treating EGFR mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM) [4][24] - Silevertinib has shown durable clinical responses in a phase I study involving patients with recurrent EGFRm NSCLC, including those with various mutation subtypes [5][8] - The company is currently conducting a phase II study for silevertinib in both recurrent and frontline settings, with initial results expected in late 2025 [6][8] - BDTX has entered a global licensing agreement with Servier Pharmaceuticals for its second asset, BDTX-4933, receiving an upfront payment of $70 million, allowing it to focus solely on silevertinib [9][23] CGEM Overview - CGEM is co-developing zipalertinib, an irreversible EGFR inhibitor targeting EGFR exon 20 insertion mutations, with Taiho Pharmaceutical [10][12] - Zipalertinib has met its phase IIb endpoint in patients with EGFR ex20ins NSCLC, with plans for a new drug application submission by the end of 2025 [11][12] - CGEM has a broader pipeline, including candidates for NSCLC and multiple myeloma, but has seen a decline in EPS estimates over the past 60 days [13][17] Comparative Performance - BDTX shares have increased by 59.8% year-to-date, while CGEM shares have decreased by 48.4%, contrasting with a 5.2% gain in the industry [19] - BDTX is trading at a lower valuation of 5.87X forward sales compared to CGEM's 15.56X [21] - The Zacks Consensus Estimate for BDTX's 2025 EPS suggests a significant increase of 125.98%, while CGEM's estimates have moved downward [15][17] Investment Outlook - BDTX is currently rated as a Zacks Rank 2 (Buy), while CGEM holds a Zacks Rank 4 (Sell) [23] - BDTX's silevertinib is positioned as a promising candidate in the competitive NSCLC market, targeting a wide range of mutations, including the C797S resistance mutation [24][25]

Core Insights - Cullinan Therapeutics is advancing its CLN-978 program across three active Phase 1 studies targeting systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and Sjögren's disease, while also in-licensing the BCMA-directed bispecific T cell engager velinotamig from Genrix Bio [1][2][4] - The company reported a net loss of $70.1 million for Q2 2025, compared to a net loss of $42.0 million for the same period in 2024, indicating increased operational expenses [9][13] - Cullinan has a strong cash position of $510.9 million as of June 30, 2025, providing a runway into 2028 for ongoing and future projects [9][10] Immunology Updates - The global Phase 1 study for CLN-978 in moderate to severe SLE is currently enrolling in the U.S., Europe, and Australia, with initial safety and B cell depletion data expected in Q4 2025 [4] - The Phase 1 study for active, difficult-to-treat RA is enrolling in Europe, with initial data anticipated in the first half of 2026 [4] - The Phase 1 study for moderate to severe Sjögren's disease is also enrolling in the U.S. and Europe following regulatory approval [4] Oncology Developments - Results from the pivotal Phase 2b portion of the REZILIENT1 study of zipalertinib were shared at the 2025 ASCO Annual Meeting, with further data expected at upcoming medical conferences [3][8] - Taiho Oncology plans to submit a New Drug Application (NDA) for zipalertinib in relapsed EGFR ex20ins NSCLC by the end of 2025, with enrollment for the pivotal REZILIENT3 study expected to complete in the first half of 2026 [3][8] - Clinical data for CLN-049, targeting relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), is set to be shared in Q4 2025 [8] Corporate Governance - The company appointed Dr. Mittie Doyle and Dr. Andrew Allen to its Board of Directors, effective August 7, 2025, bringing significant expertise in immunology and oncology [6] - Drs. Anne-Marie Martin and David Ryan will resign from the Board effective the same date [6] Financial Overview - Research and development expenses for Q2 2025 were $61.0 million, up from $36.3 million in Q2 2024, reflecting increased investment in clinical programs [9][13] - General and administrative expenses rose to $14.8 million in Q2 2025 from $13.8 million in the same period last year [13] - The total operating expenses for Q2 2025 were $75.8 million, compared to $50.0 million in Q2 2024 [13]

Financial Data and Key Metrics Changes - The company reported approximately $570 million in cash, providing a runway into 2028 based on the current operating plan [7] - The overall response rate in the RESILIENT-one study was 35%, with a 40% response rate in patients who progressed after chemotherapy [17][18] - The median duration of response was just under nine months across all groups [18] Business Line Data and Key Metrics Changes - The company is advancing multiple clinical-stage programs, including CLN978 for autoimmune diseases and CLN619 for non-small cell lung cancer [6] - Zipilertinib, the oral EGFR tyrosine kinase inhibitor, has shown promising results in patients with EGFR exon 20 mutations, with breakthrough therapy designation by the FDA [11][12] Market Data and Key Metrics Changes - EGFR mutated non-small cell lung cancer accounts for 16% of all non-small cell lung cancer, with exon 20 mutations representing approximately 12%, translating to an annual incidence of about 3,000 to 5,000 patients in the U.S. [67] - The company noted that patients with exon 20 mutations tend to have a poorer prognosis, highlighting the unmet need for effective therapies [68] Company Strategy and Development Direction - The company plans to pursue regulatory interactions for a potential U.S. NDA filing in the second half of the year [22][23] - There is an expansive development program for zipilertinib across multiple patient segments, including relapsed refractory disease and frontline settings [69][70] - The company retains 50% of the rights for zipilertinib in the U.S. and has a co-development and co-commercialization arrangement with partners at Tahoe [77][78] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the clinical profile of zipilertinib, noting its favorable safety profile compared to existing therapies [75] - The company anticipates significant uptake of zipilertinib once it becomes available, particularly as an oral option for patients [60][62] Other Important Information - The RESILIENT-two study will provide data on patients with active brain metastases and those with uncommon EGFR mutations in the second half of the year [79] - The RESILIENT-three study is ongoing, comparing zipilertinib plus chemotherapy to standard care [72] Q&A Session Summary Question: What is the efficacy of zipilertinib in patients with brain metastases? - The drug has shown encouraging preliminary data in patients with brain metastases, with good disease control observed [84][86] Question: What is the breakdown of patients in real-world settings? - Most patients are heavily pretreated, often having received chemotherapy and amivantamab before seeking other options [88][90] Question: Is there any data on the role of MET amplification in exon 20? - The response to this question was not directly addressed in the provided content, indicating a need for further research [94]

Company Overview - Cullinan Therapeutics, Inc. is a biopharmaceutical company focused on developing targeted therapies across various modalities for autoimmune diseases and cancer [3] - The company has built a diversified portfolio of clinical-stage assets aimed at inhibiting key disease drivers and harnessing the immune system [3] - Cullinan aims to create new standards of care by identifying optimal targets and developing transformative therapeutics [3] Upcoming Events - The management team will host a company event at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL [1] - An in-person event for analysts and institutional investors is scheduled for June 1, 2025, at 6:30 p.m. CT, following the oral presentation of results from the pivotal Phase 2b REZILIENT1 trial [4] - Participation in the Jefferies 2025 Global Healthcare Conference will include a panel discussion on June 4, 2025, and a company presentation on June 5, 2025 [4] Investor Relations - Webcasts of the ASCO event and Jefferies Conference presentations will be available on the company's investor relations website [2] - Investors and analysts can register for the in-person event by contacting the Head of Investor Relations [4]